Implantable Device Traceability in Panama: Mandatory Form and Reporting

1. Key takeaways

Traceability for implantable devices in Panama is a legal requirement, not a recommended practice. Article 62 of DE 490 states that traceability for implantable medical devices is mandatory (La trazabilidad para los Dispositivos Médicos implantables es obligatoria) and requires health institutions to take the measures needed to complete the established form, attach that form to the patient clinical history (historia clínica) and report it to DNDM. There are three actions in that sentence, and omitting any one leaves the obligation incomplete. The higher-level basis sits in Article 7 of Ley 90: item 5 requires DNDM to develop and maintain information systems supporting vigilance and traceability for any device, and item 7 requires DNDM to establish a National Registry of Implantable Medical Devices and Prostheses. Article 2, definition 92 of DE 490 defines traceability as the ability to track a device along the supply chain, from its origin to its final state as an object of consumption.

2. Legal basis

The provisions below connect three layers: the statutory mandate to maintain traceability systems and a national implant registry, the operational duty on health institutions to complete and file a form, and the downstream use of that data when a recall authorisation is sought. The table should be read as a chain rather than a list, because the value of the form completed in the hospital is realised only at the point where the manufacturer needs domestic traceability for a recall.

3. Expert insights

Insight 1: the duty holder under Article 62 is the health institution, but the manufacturer is caught by another provision. The subject of Article 62 is the health institution, and all three actions fall on the hospital side. Article 58.3.3, however, requires the manufacturer and importer to submit domestic traceability when a recall is filed. The two provisions interlock: the form produced by the hospital is precisely the data source the manufacturer needs later. A manufacturer that does not put the form template and completion guidance into the hospital at launch will have no data to submit when a recall arises.

Insight 2: definition 92 sets the end point at the patient, not at the distribution channel. Traceability is defined as tracking the device to its final state as an object of consumption. Combined with the requirement to attach the form to the patient clinical history, the Panamanian target is the level of the individual implanted patient, not the distributor. This is the dividing line for judging whether an existing UDI or traceability system is adequate: a system that stops at lot and distributor is incomplete under Article 62.

Insight 3: Article 7.7 creates a second track alongside the clinical record. The statute requires a national implant and prosthesis registry; the decree requires hospitals to file the form in the record and report it to DNDM. The two tracks meet at DNDM, where hospital data feed the national registry, and Article 10 further requires a public database containing safety alerts and voluntary withdrawals. For implantable products, a company is therefore connecting to a national registry and vigilance loop with DNDM at its centre.

Insight 4: traceability capability determines whether a recall authorisation can be obtained at all. Article 58 makes prior authorisation a condition of recall, and the third item of the application is domestic traceability. Read together with Article 62, the implant form is not an archival document; it is the evidence on which any future recall legally depends.

4. Practical recommendations

• Prepare a Spanish traceability form template before launch. Article 62 refers to the established form, so a company format is not acceptable. After the CCT is issued and before the first shipment, confirm the current version with DNDM and prepare Spanish completion instructions to travel with the goods.
• Make hospital training part of the launch. Two of the three actions, completing the form and filing it in the record, are performed by the hospital. A Spanish-language session for the device and surgical departments should fix the completion point at implantation and the filing route into the clinical history.
• Take granularity to patient and serial number. Under definition 92 and Article 62, lot and distributor level is not enough; bind each implantable unit to a serial number and retain the implanting institution and the implantation date.
• Connect the form data to the recall ledger. Feed the traceability output required by Article 58.3.3 so that data do not have to be reconstructed during a recall.
• Monitor progress on the national registry. The registry under Article 7.7 of Ley 90 is a statutory function, and the registration procedure follows what DNDM publishes; confirm the current position in writing at project start.

5. Verification checklist

• □ Current Article 62 traceability form version confirmed with DNDM
• □ Spanish completion instructions and a template to accompany shipments prepared
• □ Traceability granularity confirmed at patient and serial number level
• □ Completion and filing training delivered at key implanting hospitals, covering all three actions
• □ Traceability data can be exported as the domestic traceability required by Article 58.3.3
• □ Higher-level basis recorded for Article 7.5 and Article 7.7 of Ley 90
• □ Article 63 seizure, suspension and restriction powers flagged to management

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Panamanian market. Our team manages Ministry of Health (MINSA) sanitary registration applications, prepares Spanish-language dossiers, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com